Bailard Inc. Invests $7.15 Million in Boston Scientific Co. (NYSE:BSX)

Bailard Inc. bought a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 123,624 shares of the medical equipment provider's stock, valued at approximately $7,147,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bruce G. Allen Investments LLC purchased a new position in Boston Scientific in the fourth quarter worth about $28,000. Motco lifted its position in Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 372 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in Boston Scientific by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 215 shares during the last quarter. Asset Dedication LLC increased its holdings in shares of Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 235 shares in the last quarter. Finally, CNB Bank bought a new stake in shares of Boston Scientific in the 3rd quarter worth $42,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on BSX shares. UBS Group increased their price objective on Boston Scientific from $74.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday. Evercore ISI raised their price target on shares of Boston Scientific from $72.00 to $78.00 and gave the company an "outperform" rating in a report on Thursday. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 16th. Needham & Company LLC increased their price objective on shares of Boston Scientific from $71.00 to $82.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Robert W. Baird lifted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an "outperform" rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $74.27.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now owns 41,374 shares of the company's stock, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 in the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE:BSX traded up $0.39 during trading on Thursday, hitting $73.30. 8,171,396 shares of the company's stock were exchanged, compared to its average volume of 6,560,629. The business's 50-day simple moving average is $67.68 and its 200 day simple moving average is $60.37. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $74.39. The company has a market cap of $107.54 billion, a price-to-earnings ratio of 68.50, a PEG ratio of 2.42 and a beta of 0.78.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same period last year, the firm posted $0.45 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.25 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.